Price movement over the last 24 hours
ADMA Biologics Inc vs iShares MSCI Germany (DAX) — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while iShares MSCI Germany (DAX) trades at $41.26. The key difference: iShares MSCI Germany (DAX) is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | EWG | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $20.38 | $44.56 |
52-Week Low | $7.60 | $38.08 |
Enterprise Value | $2.20B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
EWG is trading at $42.66, up 0.83% with a bullish technical signal from moving averages. The stock shows strong momentum indicators but RSI suggests potential overbought conditions. Recent European market strength and German economic reforms provide positive backdrop. Dividend of $0.83 scheduled for June 2026 indicates shareholder returns commitment.
Outlook remains positive with European equity momentum and potential short-squeeze dynamics. Key risks include ECB rate hikes impacting growth sectors and German industrial employment concerns. Investment opportunity lies in European market rotation and cyclical sector strength, though valuation metrics require monitoring given limited fundamental data availability.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →